In 2021, the FDA approved the MEK inhibitor selumetinib for pediatric patients with neurofibromatosis type 1, a genetic disorder in which NF1 loss predisposes to peripheral nerve sheath tumors and other cancers (Table 1) [95,96]. This evidence concerns the gene MAP2K7 and cancer.